Correlation Between Merus BV and Mineralys Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Merus BV and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merus BV and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merus BV and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Merus BV and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merus BV with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merus BV and Mineralys Therapeutics,.

Diversification Opportunities for Merus BV and Mineralys Therapeutics,

0.52
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Merus and Mineralys is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Merus BV and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Merus BV is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merus BV are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Merus BV i.e., Merus BV and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Merus BV and Mineralys Therapeutics,

Given the investment horizon of 90 days Merus BV is expected to generate 0.88 times more return on investment than Mineralys Therapeutics,. However, Merus BV is 1.14 times less risky than Mineralys Therapeutics,. It trades about 0.08 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.01 per unit of risk. If you would invest  1,420  in Merus BV on August 25, 2024 and sell it today you would earn a total of  3,129  from holding Merus BV or generate 220.35% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy90.93%
ValuesDaily Returns

Merus BV  vs.  Mineralys Therapeutics, Common

 Performance 
       Timeline  
Merus BV 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Merus BV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Mineralys Therapeutics, 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Merus BV and Mineralys Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Merus BV and Mineralys Therapeutics,

The main advantage of trading using opposite Merus BV and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merus BV position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.
The idea behind Merus BV and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world